Skip to content
Business Company News, Medical Health Aged Care

CIMIC’s Leighton Asia wins major hospital expansion project in Hong Kong

CIMIC Group 2 mins read

CIMIC Group company Leighton Asia, in joint venture, has been selected by the Hong Kong Hospital Authority to undertake the A$4.3 billion North District Hospital (NDH) expansion project.

The project, which will generate revenue of up to A$2.4 billion for Leighton Asia, will elevate the health infrastructure in the North District of Hong Kong and provide around 1,500 additional hospital beds.

CIMIC Group Executive Chairman Juan Santamaria said: “Modern healthcare infrastructure is foundational to the well-being of communities. We are proud to bring our experience in delivering health facilities and our ‘hospital-first’ approach to this project, which puts the needs of health workers, patients, and community at the forefront. We look forward to working with the Hong Kong Hospital Authority to deliver this upgrade for Hong Kong’s Northern District.”

Leighton Asia Managing Director Brad Davey said: “Leighton Asia, is proud to be part of the team chosen for the North District Hospital expansion, a project that will set new standards in patient care and medical excellence. Our extensive experience in healthcare construction, combined with our deep understanding of local and international standards, uniquely equips us to deliver this state-of-the-art facility.”

The joint venture between Leighton Asia and China Railway First Group will construct the main works for a new acute block, a 20-storey structure covering a construction floor area of 380,000sq m, a single basement level and a mezzanine floor, and various external and landscaping works.


About us:

CIMIC Group is an engineering-led construction, mining, services and public private partnerships leader working across the lifecycle of assets, infrastructure and resources projects. CIMIC Group comprises our construction businesses CPB Contractors, Leighton Asia and Broad, our mining and mineral processing companies Thiess (joint control) and Sedgman, our services specialist UGL and our development and investment arm Pacific Partnerships – all supported by our in-house engineering consultancy EIC Activities. Our mission is to generate sustainable returns by delivering innovative and competitive solutions for clients and safe, fulfilling careers for our people. With a history since 1899, and around 30,000 people in around 20 countries, we strive to be known for our principles of Integrity, Accountability, Innovation and Delivery, underpinned by Safety.


Contact details:

Ms Fiona Tyndall, Communications T+61 2 9925 6188

Media

More from this category

  • Business Company News, Finance Investment
  • 13/09/2024
  • 13:23
Friday 13 September

MELBOURNE AIRPORT’S THIRD RUNWAY TO DELIVER LOCAL JOBS BOOST

IFM Investors welcomes the Australian Government’s decision to clear Melbourne Airport’s third runway for take-off, supporting 51,000 jobs, boosting economic activity and getting more people where they need to go. Federal Minister for Infrastructure, Transport and Regional Development and Local Government Catherine King has this week approved the major development plan for the construction of a third runway at the Airport. Melbourne Airport, an IFM portfolio company, contributes more than 146,000 jobs in Victoria and A$17.7 billion in Gross Value Added to the state economy[1]. The third runway will not only help cater for Melbourne’s growing travel and freight needs…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:40
Zenas BioPharma

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:31
Dementia Australia

New report reinforces dementia as chronic disease of 21st century

Updates to the Dementia in Australia report, released today by the Australian Institute of Health and Welfare (AIHW), reinforce that dementia is an urgent public health issue. Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 and over. Dementia Australia CEO Professor Tanya Buchanan saidthe report highlights the enormity and impact of dementia in Australia as the chronic disease of the 21st century. “Despite the growing number of Australians diagnosed with dementia – there…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.